Home World News HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy Plus... World News HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy Plus Bevacizumab or Anti-EGFR, but Negative Prognostic Factor in pMMR/MSS RAS/BRAF Wild-Type mCRC By Ogkologos - September 29, 2025 484 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a large analysis of HER2 status in patients enrolled in 8 randomised clinical trials Source RELATED ARTICLESMORE FROM AUTHOR How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research MOST POPULAR What Do You Put In Your Pocket? April 28, 2021 T-DM1 is Active and Well Tolerated in Patients with HER2-positive Metastatic... July 9, 2020 Omission of Completion Axillary Lymph Node Dissection Noninferior to More Extensive... April 8, 2024 How you can do your part in the AI transformation of... October 7, 2025 Load more HOT NEWS Cancerul în comunitatea mea: progresul îngrijirilor pentru cancer în România Cincinnati Police Are Wearing Pink Badges For Breast Cancer Awareness Exploring Coping Resources to Help with Physical, Practical, and Emotional Challenges... ESMO Gynaecological Cancers Congress 2022, 17 – 18 June 2022 Valencia,...